GNE-3511

GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a Ki of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseases[1].

Product Specifications

CAS Number

[1496581-76-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MAP3K

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/GNE-3511.html

Purity

99.54

Solubility

DMSO : 31.25 mg/mL (ultrasonic)

Smiles

N#CC1=CC=NC(NC2=NC(N3CC(F)(F)CC3)=CC(C4CCN(C5COC5)CC4)=C2)=C1

Molecular Formula

C23H26F2N6O

Molecular Weight

440.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Patel S et al. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem. 2015 Jan 8;58 (1) :401-18.|[2]Chen Jiang, et al. Neuronal Dual Leucine Zipper Kinase Mediates Inflammatory and Nociceptive Responses in Cyclophosphamide-Induced Cystitis. J Innate Immun